Company intelligence / Profile preview

Kyros

Los Angeles, California, United States

Ownership: Private
Employees: ~4
Development stage: Other

Overview

ENV105, an antibody targeting CD105, is in Phase 2 for prostate cancer and Phase 1 for lung cancer. Preliminary results focus on overcoming resistance in these cancers, with IND cleared for a glioblastoma program but without published efficacy results.

Therapeutic areas: Oncology
Modalities: AntibodySmall moleculeT cell therapy
Industry: Biotech

Partnerships

Strategic relationships with major medical centers

Beyond the preview

Go deeper on Kyros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kyros.

Explore the full profile